key: cord-0929674-sxa6oqzn
authors: Yang, Huazhen; Chen, Wenwen; Fang, Fang; Valdimarsdóttir, Unnur A; Song, Huan
title: Does antipsychotic use mediate the effect of psychiatric disorders on COVID-19? – Authors' reply
date: 2021-02-03
journal: Lancet Healthy Longev
DOI: 10.1016/s2666-7568(21)00007-6
sha: e2e0f34dc426078f6cd5cec2a38f7e97f410ff60
doc_id: 929674
cord_uid: sxa6oqzn

nan

We thank Augusto Ferraris and colleagues for their important comments on our study. 1 We share their interest in advancing understanding on the potential mechanisms that underlie our observed associations. One possibility is the potential role of psychotropic drugs, such as antipsychotic medications, as suggested by Ferraris and colleagues.

The UK Biobank has data on the use of antipsychotic medications from the baseline questionnaire and from linked primary care prescription data. Inspired by Ferraris and colleagues' hypothesis, we tested whether use of antipsychotic medications could mediate our reported associations by restricting the analysis to 415 381 indi viduals with no history of antipsychotic use (98·7% of the original study population). The results from this additional analysis were largely similar to our original results. The fully adjusted odds ratios were 1·49 (95% CI 1·32-1·68), 1·59 (1·38-1·83), and 2·04 (1·59-2·63) for all COVID-19 cases, inpatient COVID-19 cases, and COVID-19-related deaths, respectively, comparing indi viduals with psychiatric disorders to those without such disorders. Although not a full mediation analysis, these new results suggest little, if any, influence of antipsychotic use on the observed associations.

Indeed, previous studies on antipsychotic use and the risk of infection, as cited by Ferraris and colleagues, are observational and, as a result, might suffer from indication bias. In other words, it is possible that the use of antipsychotic medications is more an indicator of the severity of psychiatric disorders, and that the heightened risk of infections among antipsychotic users reflects other biological sequelae of severe psychiatric conditions rather than the medications themselves. 2 However, other psychotropic mediations might also have a role in the associations between psychiatric disorders and susceptibility to various infections, and should be the subject of further studies. For example, in our previous studies on the association between stress-related disorder and risk of life threatening infections 3 and autoimmune disease, 4 we showed a decreased relative risk of immunerelated outcomes among patients with stress-related disorder who received long-term treatment with selective serotonin reuptake inhibitors. Similarly, a protective role of benzodiazepines on community-acquired pneumonia has also been reported. 5 In conclusion, although we were not able to confirm Ferraris and colleagues' hypothesis, we agree with them that further research is needed to understand the underlying mechanisms that link pre-existing psychiatric disorders and susceptibility to infections, including COVID-19, focusing on potential genetic, environmental (including use of psychotropic drugs), and epigenetic factors.

Pre-pandemic psychiatric disorders and risk of COVID-19: a UK Biobank chort analysis

Antipsychotic drug use and pneumonia: systematic review and meta-analysis

Stress related disorders and subsequent risk of life threatening infections: population based sibling controlled cohort study

Association of stress-related disorders with subsequent autoimmune disease

The use of benzodiazepines could be a protective factor for community-acquired pneumonia (CAP) in ≤60-year-old subjects